FDA Approves First-of-Its-Kind Drug for Polycythemia Vera, Sparing Patients Frequent Blood Draws
The Food and Drug Administration approved Mimrylo (rusfertide) on Friday, August 28, the first drug of its kind for polycythemia vera, a rare blood disorder that causes the body to produce dangerously excessive amounts of red blood cells. The approval gives patients a new treatment option specifically for those whose disease hasn’t been adequately controlled by existing therapies.
What the Drug Does
Polycythemia vera causes excess red blood cells that can thicken the blood and raise the risk of serious cardiovascular complications, including blood clots, stroke, and heart attack, according to the FDA’s own announcement. Mimrylo is the first approved treatment for the condition that mimics hepcidin, a hormone that naturally regulates iron levels in the body. By limiting the iron available for producing new red blood cells, the drug helps reduce their overproduction and keep overall red blood cell levels under control.
Tanya Wroblewski, director of the Division of Nonmalignant Hematology within the FDA’s Center for Drug Evaluation and Research, described the significance of the approval in the agency’s statement. “People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction,” Wroblewski said. “Today’s approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden.”
Why Reducing Phlebotomy Matters
A key treatment goal for polycythemia vera patients is keeping hematocrit — the proportion of red blood cells in the blood — below 45% to reduce cardiovascular risk, according to coverage from FINCHANNEL relaying the FDA’s announcement. That target has traditionally required phlebotomy, a procedure in which blood is drawn from a vein specifically to reduce red blood cell counts. Even with existing treatments, some patients continue needing frequent phlebotomies, creating an ongoing burden that Mimrylo is specifically designed to help address.
The Clinical Evidence Behind the Approval
The FDA’s decision was based on data from the Phase 3 VERIFY trial, a double-blind, placebo-controlled study of rusfertide in polycythemia vera patients, according to AJMC. The trial’s results were significant enough to be presented during a plenary session at the American Society of Clinical Oncology’s 2025 annual meeting — a notable distinction, since AJMC described it as a rare occasion for a study specifically focused on polycythemia vera to receive that level of prominence at the major cancer research conference.
According to earlier data on the trial presented at the American Society of Hematology’s 2025 meeting, cited by AJMC, rusfertide demonstrated durable response and sustained hematocrit control in polycythemia vera patients over longer-term follow-up, with 52-week data specifically showing the drug spared most patients a phlebotomy procedure for 32 weeks and improved their quality of life.
Who Makes the Drug and How Many Patients It Could Help
Mimrylo was developed jointly by Takeda Pharmaceutical and Protagonist Therapeutics, according to Endpoints News. Polycythemia vera is classified as a rare, slow-growing blood cancer that affects roughly 90,000 Americans, according to the Manila Times.
Teresa Bitetti, president of Takeda’s global oncology business unit, told Reuters, as reported by the Manila Times, that the drug would be made available to patients within 48 hours of the FDA’s approval — an unusually fast rollout timeline that reflects the drug’s designation and the existing manufacturing and distribution infrastructure already in place ahead of the approval decision.
FAQ
What is polycythemia vera? A rare blood disorder in which the body produces excessive numbers of red blood cells, thickening the blood and increasing the risk of blood clots, stroke, and heart attack. It affects roughly 90,000 Americans.
How is Mimrylo different from existing treatments? It’s the first approved polycythemia vera treatment that mimics hepcidin, a hormone that regulates iron levels in the body, working by limiting the iron available to produce new red blood cells rather than through the mechanisms used by prior therapies.
Who makes Mimrylo? Takeda Pharmaceutical and Protagonist Therapeutics developed the drug together.
What clinical evidence supported the approval? Phase 3 data from the VERIFY trial, a double-blind, placebo-controlled study, which showed the drug helped most patients avoid phlebotomy procedures for extended periods while improving quality of life.
When will the drug be available to patients? Takeda said Mimrylo would be available within 48 hours of the FDA’s August 28 approval.
Conclusion
Mimrylo’s approval offers polycythemia vera patients a genuinely new treatment mechanism rather than an incremental improvement on existing options, specifically targeting the hormone pathway responsible for regulating red blood cell production. With clinical trial data showing meaningful reductions in the need for frequent phlebotomy procedures — a persistent burden even for patients on existing therapies — the drug’s rapid rollout timeline suggests both the company and regulators see significant near-term demand among the tens of thousands of Americans living with this chronic condition.
Sources: U.S. Food and Drug Administration, Endpoints News, CancerNetwork, AJMC, Manila Times, Takeda Pharmaceutical newsroom, RTTNews, MedicalDialogues, FINCHANNEL (reporting dated August 28-30, 2026).